Percentage of Males with Nocturia Who Have BPH
While the exact percentage of males with nocturia who have BPH is not directly stated in the guidelines, the evidence strongly indicates that BPH is the predominant cause of nocturia in men over 50, with approximately 60% of men aged 60 having BPH and 80% by age 80, and nocturia being present in the vast majority (75-90%) of symptomatic BPH patients. 1, 2
Understanding the Relationship Between Nocturia and BPH
The relationship between nocturia and BPH is bidirectional and complex:
BPH is nearly ubiquitous in aging males, with prevalence reaching 60% by age 60 and 80% by age 80, making it the predominant cause of urinary frequency in men over 50. 1, 2
Nocturia prevalence increases dramatically with age: 30% of men aged 50-54 have nocturia ≥2 times per night, rising to 60% in men aged 70-78. 3
Among men with BPH, nocturia is extremely common: approximately 75-96% of men with symptomatic BPH have at least one episode of nocturia, and 75.8% have two or more episodes per night. 4
In Spanish populations with diagnosed BPH, nocturia prevalence reaches 83% in patients ≥60 years old, and it is reported as the most bothersome symptom in patients with BPH. 5
Critical Diagnostic Considerations
The presence of nocturia does not automatically indicate BPH, as multiple etiologies must be considered:
Nocturnal polyuria is a major contributor: 27.7% of men with nocturia have nocturnal polyuria (defined as nocturnal urine production >90 ml/h), compared to only 8.0% of men without nocturia. 6
BPH is an independent risk factor for nocturia, but other conditions including heart failure, urinary tract infections, diabetes, bladder cancer, urethral strictures, and bladder stones can produce identical symptoms. 1, 7
Voiding diaries are essential for diagnosis: patient voiding diaries recording frequency and volume are particularly helpful when nocturia is the predominant symptom, as they distinguish between bladder storage problems and nocturnal polyuria. 8
Clinical Implications
Digital rectal examination should be performed to assess prostate size and exclude locally advanced prostate cancer, though DRE tends to underestimate true prostate size. 8, 1
Serum PSA measurement should be offered to men with ≥10-year life expectancy to exclude prostate cancer and predict BPH progression risk, as men with higher PSA levels have increased risk of prostate growth, symptom deterioration, and acute urinary retention. 8, 1
Urinalysis is mandatory to screen for hematuria and urinary tract infection, as bladder cancer, carcinoma in situ, UTIs, and bladder stones can produce identical lower urinary tract symptoms. 8, 1